
The investment doubles the company’s capacity to meet increasing demand for its biologics contract testing and biosimilar characterization services.
The investment doubles the company’s capacity to meet increasing demand for its biologics contract testing and biosimilar characterization services.
The new service offering includes feasibility studies, process and analytical development, and scale-up from milligram to gram quantities required for pilot and subsequent commercial scale.
The contract is a memorandum of understanding for the manufacturing by MaSTherCell of clinical batches of TxCell’s Ovasave.
World Courier receives pharmaceutical storage and transportation accreditation in the United Kingdom.
The technology platform measures protein-protein interactions.
Katsuaki Kaito has been named president of Shimadzu Scientific Instruments.
CSafe and AES will support controlled-temperature shipping through the Basel, Switzerland airport from their new service center.
Evans Analytical Group expands into the pharmaceutical/biopharmaceutical industry with acquisition of ABC Laboratories.
The Mobius 2000-L single-use bioreactor from EMD Millipore offers configurable software, hardware, and single-use Flexware assemblies for suspension and adherent cell-culture applications.
Consisting of a needle hub and a needle shield, the new syringe closure system is partly produced by means of a two-component injection molding process of polypropylene and thermoplastic elastomer.
Charles Rivers strengthens its endotoxin testing and bacterial identification detection capabilities with the addition of Celsis’ products.
Catalent’s licensing of Excelimmune’s antibody combination therapy platform can enable more consistent, cost effective production of antibody combinations.
Catalent licenses Excelimmune’s antibody combination therapy platform toenable the manufacture of multiple recombinant antibodies in a single batch culture.
According to Sartorius Stedim Biotech, this acquisition expands its service offering for process development.
The addition of a new manufacturing line at Lonza’s Portsmouth, NH site enables Alexion to add dedicated product supply for 10 years.
The new facility expands the company’s commercial manufacturing capability at its Bend, Ore. site.
Australian company, Genea Biocells, will open a facility in San Diego, California for cell and culture-media manufacturing and R&D.
The new column features Natrix’s signature macroporous hydrogel.
IDT Biologika acquired Aeras' vaccine manufacturing facility, and the companies will work together on tuberculosis vaccine development.
apceth has completed a major GMP inspection for two medicinal products. The two cell and gene therapy products are now included in the company’s GMP manufacturing license according to §13 of the German Medicines Act (AMG).
BioSC Lab is the first in a line of next-generation chromatography equipment for protein purification in batch and continuous modes.
Lonza’s planned facility will be used to develop and manufacture viral gene therapies and virally modified cell therapies
A new SGS Life Science Services laboratory outside Paris is designed for bio/pharmaceutical quality control testing.
BioSC Lab biochromatography system performs protein purification in batch and continuous modes.
Dry media powder for the production of biotherapeutics and vaccines will be produced in a new facility in Scotland, in addition to an existing facility in New York.
A new GMP facility in Massachusetts will produce enzymes and other reagents for in-vitro diagnostics.
The supplier will add Allied Laboratories and AR Brown to its list of global partners.
A year after its merger with DSM Pharmaceutical Products, Patheon announces that it has filed an IPO.
A new demonstration facility in New York gives Sartorius’ customers hands-on access to bioprocessing systems and lab instruments.